Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
Aastrom Receives Phase II NIH Grant to Support Further Development of Its Proprietary Stem Cell Manufacturing Systems Ann Arbor, Michigan, October 18, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that it has received a Small Business Innovation Research Phase II grant from the
Alan L. Rubino Elected to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, September 30, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Alan L. Rubino, a Principal with Watchung Partners, has been elected to the Company's Board of Directors.
Aastrom Biosciences' CEO to Present at the UBS Global Life Sciences Conference Ann Arbor, Michigan, September 23, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, will present at the UBS Global Life Sciences
Aastrom Biosciences, Inc. Reports Fourth Quarter 2005 Financial Results Ann Arbor, Michigan, September 8, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported financial results for the fourth quarter and fiscal year ended June 30, 2005. The Company also reported significant clinical and
Aastrom Announces Its Fourth Quarter and Fiscal Year End Investor Conference Call Ann Arbor, MI, September 7 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Fourth Quarter and Fiscal Year End FY2005 Investor Conference Call When: Thursday, September
Stephen G. Sudovar Elected to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, August 2, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Stephen G. Sudovar, former President and CEO of EluSys Therapeutics, Inc. and former President of Roche Laboratories, Inc., has
Aastrom Biosciences, Inc. Added to Russell 3000 Index Ann Arbor, Michigan, June 28, 2005 - Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it was added to the Russell 3000® Index effective at the close of market on Friday, June 24, 2005.
